Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Novo Holdings will acquire Catalent for $63.50 a share in cash.

Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk

Novo Holdings, the holding company of Novo Nordisk , will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-loss drug Wegovy, the companies said on Monday.

Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity

Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's close. The deal is a 39% premium to Catalent's close before it announced a strategic review.

Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion

Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration.

Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction

COPENHAGEN, Denmark & SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an e.

Novo Holdings to Acquire Catalent

Novo Nordisk's CEO Lars Fruergaard Jorgensen confirmed on Wednesday that Catalent's Indiana plant in the United States has started filling injection pens for its obesity drug Wegovy, helping to boost output of the popular weekly injection.

Catalent's Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the second quarter of fiscal year 2024 ended December 31, 2023, before the market open on Friday, February 9, 2024. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET on the same day. Catalent invites all interested parties to listen to the webcast a.

Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced its targets to reduce greenhouse gas emissions (Scope 1 and 2) by 42% by 2030. The company also committed to engaging with its suppliers, of purchased goods and services, capital goods, and upstream transportation and distribution, such that 70% of their emissions will have reduction goals aligned with science-based targets.

Catalent Commits to Reducing Greenhouse Gas Emissions by 2030

Amgen

Centene

Cencora Inc

Gilead Sciences

Medtronic

Merck

Moderna

Regeneron Pharmaceuticals

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

Allstate

Arista Networks

Intuitive Surgical

Eli Lilly

NVIDIA

Palo Alto Networks

The S&P 500 rebounded last week near record highs, but is up just 0.2% so far in 2024. These are the index's top performers so far.

These 9 Stocks Are Running To Start 2024

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 5:15 p.m. ET. A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event. About Catalent Catalent, Inc., is.

Catalent, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Carnival

Chipotle

Expedia

Illumina

Intel

Warner Bros Discovery Inc

Zions Bancorp

Talk about a strong finish. Investors who hung onto the top S&P 500 stocks this year ended up much richer for the effort.

12 Stocks Turn $10,000 Into $320,800 In 12 Months

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that its wholly owned subsidiary, Catalent Pharma Solutions, Inc., as borrower, and certain other wholly owned subsidiaries of Catalent, entered into an amendment, dated as of December 19, 2023, to its existing credit agreement for the issuance of new incremental term loans in an aggregate amount of $600 million, which was u.

Catalent Announces Closing of Incremental Term Loans

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Catalent (CTLT) Up 4.1% Since Last Earnings Report: Can It Continue?

Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) announced today that the Company has received written notification (“Notice”) from the New York Stock Exchange (“NYSE”) that it has officially regained compliance with the NYSE continued listing standards. Following the filing by the Company on December 8, 2023 of its Annual Report on Form 10-K for the year ended June 30, 2023 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023,.

Catalent Regains Compliance with NYSE Continued Listing Standards

Hope you didn't bail out of S&P 500 stocks after three-straight months of losses. November turned into a big moneymaker.

11 Stocks Turn $10,000 Into $230,769 In 11 Months

Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.

Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales

The headline numbers for Catalent (CTLT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Catalent (CTLT) Reports Q1 Earnings: What Key Metrics Have to Say

Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.

Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential

Syringe maker Catalent (CTLT) said soaring demand for injectable weight-loss drugs could lead to big revenue gains, and shares surged over 11%.

Syringe Maker Catalent Anticipates Boost From Demand for Injectable Weight-Loss Drugs

Catalent, Inc. (NYSE:CTLT ) Q1 2024 Earnings Call Transcript November 15, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President of Investor Relations John Greisch - Executive Chair of Board Alessandro Maselli - President and Chief Executive Officer Matti Masanovich - Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Luke Sergott - Barclays Dave Windley - Jefferies Justin Bowers - Deutsche Bank Jack Meehan - Nephron Research John Sourbeer - UBS Max Smock - William Blair Derik De Bruin - Bank of America Paul Knight - KeyBanc Eric Coldwell - Baird Rachel Vatnsdal - JP Morgan Thomas Kelliher - RBC Capital Markets Operator Hello all, and welcome to Catalent's First Quarter Fiscal Year 2024 Earnings Call. My name is Lydia and I'll be your operator today.

Catalent, Inc. (CTLT) Q1 2024 Earnings Call Transcript

Catalent shares added more than 11% after the contract drugmaker's preliminary first quarter earnings topped expectations and it reaffirmed its full-year fiscal 2024 guidance. For the quarter ended in September, Catalent reported a 4% year-over-year drop in revenue from $1.02 billion to $982 million, above Wall Street estimates of $933.2 million.

Catalent doubles down on full year outlook as preliminary 1Q earnings beat estimates

Contract drug manufacturer Catalent on Wednesday beat Wall Street estimates for quarterly revenue as production showed signs of improvement on the back of a change in management.

Catalent beats quarterly revenue estimates

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced preliminary financial results for the first quarter of fiscal 2024, which ended September 30, 2023. “As Catalent continues to execute our strategy to enhance value for our stakeholders, the strength of our internal pipeline and our solid first quarter financial performance give us the confidence to reiterate our guidance for.

News for Catalent Stock (CTLT)